SP

ReviewIncont Pelvic Floor Dysfunct 2012; 6(3):63-68

�� !"#$%&'()*+,-./01234

��

�� !"#$% ��

�� !"#$%&'()*+,-.),/016�� !"#$%&'()�� !"#$ E-mail: Lwy0912@yahoo.com

��

Perc

ent C

hang

e (P

SA, Q

max

, VO

L) 8

6

4

2

0

-2-4

-6

-8

-10

-1240-49 50-59 60-69 70+

SX R

aw C

hang

e

0.6

0.5

0.4

0.3

0.2

0.1

0

PSA

Qmax

VOL

SX

� 1K �� !"#$Olmsted�� !"#$%&'()*+�� !EPSAF�� !"#$%&'($)*+,-EQmaxF�� !"#$%&'()*+,-.EVOLF���� !"#$%&'()*+,-.�(/0123(�� !"#$ 60~69�� !"#$x1z�

Age Group

�� !"#$%&'( !"")*+,-./ !"0

�� !"#$%&'(� $)�*+,-./01234

�� !"#$%&'(�!)#*+'(,-.(/012'

�� !"#$%&'()*+,-./0123456789

�� !"#�$%&'% ()*'+,%-./012

�� !"#$%&'()*+,-./01234567

�� !"#$%&'()*+,-./01234�56,

�� !"#$%&'()*+,&-.$/0&123456

�� !"#$%& 5α�� �� E5α-reductase inhibitor,

5ARIF�� !"#$%&'()*+,-./0"123$4

�� !"#$% &'()*+,-./012345678

�� !"#$%&'()*+,-./0123456-78

�� !"#$%&'()*+��,-.E1F�� !"#$%

�� !E2F�� !"#$%&'()*+,-./E3F�� !

�� !"#$%&'()*+,-E4F�� !"#$%&'(

�� !

�� !"#$%&'(

�� !"#$%&'()20~40�� !"#20 mL�40

�� !"#$%&'()*+,-./01"%&*2345

�� !"#$%&30 mL�� !"#$%&'()*+,$

�� !"#$ 2006�� !"#$%& 2,115�� !"#

1990�� !"#$%&'(Olmsted�� !"#$%&'(

�� !"#$%&'()*+,-./25%�� !"#$!

�� !"#$%&'()*+,-+,!./0123456

�Etransrectal ultrasound of prostate, TRUS-PF�� !"#$%&

�Eprostate specific antigen, PSAF�� !"#$%Emaximum uri-

nary flow rate, QmaxF�� 2�� !"#$%&'()*+,-

2002�� !"#$%&'()*+,-./01234567

�� !"#$%&'()*+,�-./012345678

�� !"#$%&'()*+,-./x1z�

��1�� !"#$%&'()*+,-./0123

�� !"#$%&'()*+,-."/��0123%45

�� !"#$%&'()*+,-./��*01234*5

�� !"#60~69�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,!-."#/0123456

�� !"#$%&'()*+,-./01)*+234-.

�� !"#$%&'()*+,-#./01#23425

�� !"#$%&'()*+,-./0123,45Ep=0.05F

�� !"#$%&'()*+,-./Ep=0.06F�� !"#$

�� !"#$%&'()*+,Ep=0.20F�� !"#$%&'

�� !"#$%&'()*"#$+,-./012345"

80%�� !"#$%&'(�)*+,-.2�� !"#$

�� !"#$%&'()*+,-&'(./#012350%

�� 90%�� !"#$%&'()*80%�� !"#$%

�� !"#$%&'()*+,-./012-34()*5

�� !"#$%&'()*+",-./0123$4567

�� !"#$%&'()"#$*+,-./�012345

�� !"#"$%&'()*+,-.

�� !" 2010�� !"#$%&'x2z�� !"#$

�� !"#$%&'(�� !)*2�� !"#$%&'

� 446�� !"#$%&' 40~79�� 2�� !"#$%

�� !"#$ 10�� !"#$%&'()*2�1��3�

�� !"#$%&'()*#$%+, -.#$%+,/0

2�� !"#$%&'()*+,-./012345'()

�� !"#$%&'()*+��", 2 �� !"#$

E25%~75%F�� 32.6�� !"#$%&'()*+,-

2.2%�� !"#$%&'()*+,-./02�� !"#

�� !"#$%&'()*+$,-./012345678

SQ

Review

� 1K �� !"#$%&'()*+,-./0123%456#7%89%:;.<=>?@A)=BC>DE.FG/�� !�� !"#x3z

Total IPSS

All patients (n=729) Mild (<8; n=71) Moderate (8-19; n=392) Severe (>19; n=266)

Mean SD Mean SD Mean SD Mean SDSignificance

Age (years) 63.5 8.4 63.7 8.0 63.8 8.8 63.0 7.9 NSQmax (mL/s) 11.5 5.2 13.8 7.0 11.9 5.2 10.3 4.3 SProstate volume (cm3) 43.0 20.0 40.4 20.0 45.0 21.0 42.0 19.0 NSResidual urine (mL) 48.0 71.0 44.0 86.0 41.0 61.0 60.0 80.0 SIPSS total 17.0 7.0 5.0 1.9 14.1 3.2 24.5 3.6IPSS voiding 9.7 4.8 2.6 1.8 7.9 2.9 14.4 3.0IPSS filling 7.3 3.4 2.5 1.8 6.3 2.6 10.0 2.4

IPSS=International Prostate Symptom Score; Qmax=maximum flow rate; SD=standard deviation; NS=not significant; S=significant

�� !"#$%&'()*+,-.10��20�� 30��

�� !"#$%&'()*+,-./0123� !45"

�� !"#$%&'()*+ ,-./01)*23456

�� !"#

�� !"#$%&'()*+,%-./012.345

�� !" #$%&'()*+1996��Urology�� !"

�� !"!#$%&'()*x3z��803�� !"#$%&

�� !"#$%&'()*+,-./012+,*34��

�� !"EInternational Prostate Symptom Score, IPSSF�� !"

�� !"#$%&#$'()*+,-./0123)456

E�1F�� !"#$%&'()*+,-./01234567

�� !"#$%&'"()"*+,-./0123.45/

�� !"#$%&'()*+,�-./ 0123456$

�� !"#$%&'()*+#,-./0&1234567

�� !"#$%&'()*+,-$%./"01)2345

�� !"#$%&'()*!+,-./012,34!56

��

�2012�� !"#$%&'()*+,-./01(23

�� !" CombAT=ECombination of Avodart and TamsulosinF�

�� !"#$%��&'()*+,-./0123456

�� !"#$%&'()*+, CombAT�� !"#$ 4

�� !�"50�� !"#$%&'()*+1.5~10 ng/mL�

�� !"# > 30 mL� IPSS > 12�� !"#4,844�� !

�� !�"#$%Avodart�Tamsulosin�� Avodart��

�� Tamsulosin�� !"#$%&'(#$)*+4��

�� !"#$%&'()*+,�-./012345678

�� !"#$%&'()*+,-./0"1 IPSS ≥ 20 ��

�� !"# ≥ 40 mL�� !"# < 10 mL/sec�� !"

> 50 mL�� !"#$%&'()*+,-./ 314�� !

�� !" 1.9%�� !" Avodart � 9.5%�� !"#

Tamsulosin�22.9%�� !"#$%&'()*!+,#-.

�� !"#$%&'()*+",$-'./'012345

�� !"#$%&'()*+,-./0123(45678

�� !"#$%&'()*+,-./ Avodart � Tamsulo-

sin�� !"#$%&'()*+,-./0(�123456

��

�� !"#$%&'()*+,-.

1997�� !"#$%&'()*+,-./012345

�� Etransition zone index, TZIF�� !"#$%&'()*+

�� x4z�� !"#150�� !"#!"$%&'()*+

�� !"#$%&'()*+,-./()*0123456

�� !"#$%&'()*+,-. !+/012"3�4

�� ��!"#$%&'!()*+,- ./012345

�� !"#$%&'()*+,-%./0"#12-%34

�� !"#$%&'()*+,-./0123,-456#

�� !"#$%&'()*+,-./0123-./456

�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,-./0)*+123-

�� !"#$%&'()�*+,-. !/0123456

�� !"#$%&'()*+,-$./012'34567

�� !"#$%&'()*+,-./0123456701

�� !"#$%&'#"()*+,-./01234567

�� !"#$%&'()*+,-./012345678*

�� !"#$��%&'( !)*+,-(./01234

�� !"#$%&'()*+,&'-./01234567

�� !"#$%&'()*+

��2006�� !"#$%&'()*+,-./0)12

�� !"#$%��&'()*+,-./012%�� !

�� !"#$% &'(x5z�� !"#$ The Journal of

Urology�� !"#$%&'()*Olmsted�2,115�� !

SR

Review

� 2K �� !""#$%&'()*+,-%&./0EIPPF��� !"#$%&'()*+,-.��/'()*-�� !"#$%&'()*+,-x6z�

Bladder

IPP

Prostate

� 3K �� !"#$%&'()*+�� ,-'./012�� !"#$%&'()*+,-./012%&'3�� !"#$%&'()*+,-./0123"45�� !"#$%&'()*+,-./01%2345�� !"#$x7z�

Type 1 Type 2 Type 3

TZ TZ TZ

CZ

CZCZ

PZPZ

PZ

�� !"#$%1990�� !"#$%&'()*+,-./

�� !"#25%�� !"�#$%&'()*+,-./0

�� !"#$%&'()*+,-./012345678 2

�� !"#$%&'($!)*2004�� !"#5�� 8

�� !"#$%&'()*+,-./#012336�� !

�� !"#$%&'()*+,-./0'()12345&

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'()*+,*-./01234 !56

�� !"#$%&'()*+,-.�/01 !"23'4

�� !"#$%&'()*+,-./%01#$23456

�� !"#$%&'()*+,-�./"01234567

�� !"#$%&'()*+,-./012��!3456

�� ! "#$%&'()*+,-./012345678

�� !"#$%&'()*+,-./0123456!78

�� !

�� !"#$%&'()*+,-./0

�� !"#$%&'()*+,-./012+�� !

�� !"#$%&'()*+,-./(01"2 !345

�� !"#$%&'()*+,-./01234%5678

�� !"#$%&'()2005�� !Urology�� !"#

�� !""#$%&'()*+,-%&./0Eintrave-sical

prostatic protrusion, IPPF�� !"#$x6z�� !"#$%&'

�� !"#$%�&'()*+,-.�' IPP < 0.5 cm ��

�� IPP��0.5~1 cm�� !"# IPP > 1 cmE�2F�� !

�� !"#$%&'()*+!"#$',-./01234

�� !"#$%Spearman's rho ==0.624�� !"#$%&'

�EDopplerF�� !"#$%&'()'*+,-.!/012

�� !"#$� %&'()*+,-./0123456%

�� !"#$%&'()*+,-./0123456789

�� !"#$%&'()*+,-./01234#5678

�� !"#$%&'()*+,-./0123456(78

�� !"#$%&'()*+,-./0123$%4567

�� !"#$%&'

�2009�� !Urology�� !"#$%&'()*+,

�� !"#$%&'()*+,-./0123456789

�� !"x7z�� !"#157�50�� !"#$%&$%'

�� !"#$%&'(IPSS�� !"#$%&Equality of life,

QoLF�� !"#�$%&'()*+,�-./012345

�� !"#$%&'()*+,-./0123456781

�� !"#$%&'()*+��,-./(0123)*+

�� !"#$%&'()*+",-./01234 567

�� !"#$%&'()*+,-./012345678'

�� !"#$%&'()*+,-./0123'45678

�� !"#$%&'()*� !+,-./0,1/2,3

�� !"#$%&'()*+,-.E� 3F�

�� !"#$%&'&()*+,-." !/0123

�� !"#$%&'()*��+,-./0!1+2345

�� !"#$%&'()*+,-./ 012345678

�� !�" #$%&'()*+,*-#./01234!

�� !"#$%&'()*+,-./01234567)8

�� !"#$%&'()*+",$-./

�� !"2010�� !"#$%Urology�� !"#$

�� !"#$%&'�� ()*+Eprostatic urethral angle,

PUAF�� !"#$%&'()*+x8z�� !"#$%260�

�� !"#$50�� !"#$%&'()*+,-./0!

�� ! IPSS�� !"#$%&'�()*+,-�./0

�� !"�# $% &'()* +,-./012345

�� !"#$%&'()*+,-"./01$%&234$

�� !"#$%&� !"#'()*+� !,-./0&

�� !"#$%&'()*+,-./012345 678

�� !"#$�%&'(�)*+#,-. /01234E�

SS

Review

� 3K �� !"#$=≥ 34˚�� !"#$%&'()*+�,-#$%IPSS�� !"#$%&'(� )*+,-./0123�� !"#$%&'( !")*+,-./01234

Mean

PUA < 34˚ PUA ≥ 34˚ P-value

Number 133 139Age (years) 62.3±8.6 62.6±10.4 0.775Prostate-specific antigen (ng/mL) 1.4±1.1 1.4±1.3 0.831Transrectal ultrasonography

Total prostate volume (mL) 28.6±5.4 28.5±5.7 0.833IPSS

Storage symptoms 6.7±3.6 7.5±3.6 0.061Voiding symptoms 11.7±5.1 13.7±4.4 0.001Total score 18.3±7.1 21.2±6.9 0.001Quality of life index 3.6±0.9 3.8±0.8 0.091

PUA=prostatic urethral angle; IPSS=International Prostate Symptom Score

� 2K �� !"#$%!"&'()*+,-.!/+0123!456&'!7892:;*+<=>x8z

MeanP-value Correlation coefficients P-value

PUA < 35˚ PUA ≥ 35˚

Transrectal ultrasonographyTotal prostate volume (mL) 33.1±1.6 (11.3-139.8) 41.9±1.9 (14.0-149.8) < 0.001 0.288 < 0.001Transition zone volume (mL) 12.5±1.3 (1.0-105.9) 18.6±1.4 (2.4-95.0) 0.001 0.258 < 0.001Transition zone index 0.3±0.0 (0.1-0.8) 0.4±0.0 (0.1-0.9) < 0.001 0.240 < 0.001

Urodynamic studyMaximum urethral closure 71.3±2.2 (30.0-148.0) 80.2±2.1 (31.0±167.0) 0.004 0.140 0.035 pressure (cmH2O)Detrusor pressure at Qmax 44.3±1.6 (12.0±118.0) 50.4±1.6 (4.0±104.0) 0.008 0.183 0.003 (cmH2O)

PUA=prostatic urethral angle

2F�

�� !"#$%&' PUA > 35˚ � PUA < 35˚�� !"

�� !"#$%&'()*+,E�4F�� !"#$%&'(

�� !"#$%&'()*+,-#./012345678

�� !"#$%&'()*+,-./01234-5%67

�� !"#$%&'()*+,-./01234"5678

�� !"#$%&'()*+,-./0

�� !"#$%&'()*+ !",-./0�123

�� !"#$%&'!()*+,-./012345678

�� !"#$%&'()*+,"-./#0&PUA ≥ 34˚�

�� !"#$%&'()*+,-"#$IPSS�� !"#$

IPSS�� !"#$%&'()*+,-./0123 456

�� !"#$%&'()*+,E�3F�� !"#$%&'(

�� !"#$%&'()*"+,-./012'()*34

�� !"#$%&'()*+,-./012$3,4567

��

�� !"#$%&'()*+,-./01234-56

� 4K �� !"#$EPUAF�� !"#$%&EBOO indexF��� !"#$EAF�� !"#$ > 35˚�� !"#$�=< 35˚�� !""#$%&'()*+,-./0�EBF�� !"#$%&'()*+,-./012345�� !"#x8z�

35

30

25

20

15

10

5

0

100

75

50

25

0

-25

PUA

BO

O in

dex

BO

O in

dex

PUA < 35˚ PUA > 35˚

P=0.006A B

0 20 40 60 80 100

�� !"#$%&'(")*+,-./012345678

�� !" < 10 mL/sec�� !"#$%&'() 52.2±7.2 �

�� !"#$%& 20 mL/sec�� !"#$%&'()*+

ST

Review

� 4K �� !"#$%&'()*+,-./" !0123456789:;<$%=>?@A12�� !"Dutasteride�� !�� !"#$�� %&'(#)*+,-./01'(

750 Efficacy of dutasteride on storage and voiding functions in patients with benign prostatic hyperplasia: A pressure-flow study

Baseline 2M 6M 12M

Prostate volume (mL) 56.6 49.5 42.7 39.4PdetQmax (cmH2O) 81.0 71.0 61.0 60.0

��

��

��

��

��

39.7±7.9�� !"#$%&'()*+,-./0123&4

�� !"#$%&'()*+,-./0123456*7&

�� Ep=0.003F�� !"#$%&'()*+,-./%&'

�� !"#$%&'� ()*+,-./01234567

�� !"#$%&'()*!+,-./012345(6

�� !"#$%&'()*+,-./0123"45678

�� !"#$%&'()*+,-./01234��567

�� !"#$%&'()*

�� !"#$%&'()*+,2010�International Jour-

nal of Urologyx9z�� !"#$%&1997�1��2003�12�

�� !"#$%#$&'()*+,-./01234567

�� !"#$%&'()� *IPSS�� !�"�#$��

�� !"#$%&'()*+,-./0123456��

�� !"#$%&"'%(")*%+",-./01#23

�� !"#$%&'()*+,Eα-blockerF��5α�� ��

�� !"#$%&'()*( > 100 mL�� !"#$%&

�IPSS�� !"#4�� !"#$%&'()*+,-./

�� !"#$%&'()*(+,-./012345678

�� !"#$%&'%(&)%*+,-./0123456

�� !"#$%&'()*+,-.#/0123456#7

�� !"#$%&'()*+,-./)0123456!7

�� !"#$%&'()*+,-./01#2345678

�� !"#$%&'()*+,-./012345,678

�� !"#$%&'()

�� !"#$%&'()*+

�� 5� �� Dutasteride�� !"#$%&'(

�� !"#$%&'()*+,-./'012�3!456

�� !"#$%&'()*+,-./0123456!7

�� !"#$%&'()*+,-./01234'%&56

�� !"#$%&'()*+,-./ 1 2 �� !"

Dutasteride�� !"#$%&'()*+,-56.6�� 39.4

mL�� !"#$%&'(81 cmH2O�� 60 cmH2OE�4F�

�� !"CombAT�� !"#$%&'()*+,-.

�� ! > 55 mL�� !"#$%&'()*+,-./01

�� �!"#$ 5� �� !"#$%& 70%�� !

�� !"#$%&'()*+,-./01 5� ��

�� !"#$%&'()*+,-./0123456789

�� !"#$%&�'()* Campbell�� ! 10�� !

�� !"#$%&'()*+,�-./01234567

�� !"#$%&'()*+,-./0"12345678

�� !"#$%&'()*+,-./012

��

�� !"#$%&'()*+, -./0123456

�� !"#$%&"'()*+,-./0"'123456

�� !"#$%&'()*+,-./0%12345678

�� !"#$%&'()*+,%-./012"34567

�� !"#$%&'()*+,-./0123&45)67

�� !"#$%&'()*+,-./0123,45678

�� !" 5� �� !"#$%&'()*+,-./

�� !"#$%&'()*+,-./�012345678

�� !"#

�� !

1. St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME,Jacobsen SJ: Tracking of longitudinal changes in measures of be-nign prostatic hyperplasia in a population based cohort. J Urol 2006;175:1018-1022.

2. Lieber MM, Rhodes T, Jacobson DJ, et al: Natural history of benignprostatic enlargement: Long-term longitudinal population-basedstudy of prostate volume doubling times. BJU Int 2010; 105:214-219.

3. Ezz el Din K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Ro-sette JJ: Correlation between uroflowmetry, prostate volume,postvoid residue, and lower urinary tract symptoms as measuredby the International Prostate Symptom Score. Urology 1996; 48:393-397.

4. Witjes WP, Aarnink RG, Ezz-el-Din K, Wijkstra H, Debruyne EM, dela Rosette JJ: The correlation between prostate volume, transitionzone volume, transition zone index and clinical and urodynamic in-vestigations in patients with lower urinary tract symptoms. Br J Urol1997; 80:84-90.

5. St Sauver JL, Jacobson DJ, Girman CJ, McGree ME, Lieber MM,Jacobsen SJ: Correlations between longitudinal changes in transi-tional zone volume and measures of benign prostatic hyperplasiain a population-based cohort. Eur Urol 2006; 50:105-111.

6. Nose H, Foo KT, Lim KB, Yokoyama T, Ozawa H, Kumon H: Accu-

SU

Review

racy of two noninvasive methods of diagnosing bladder outlet ob-struction using ultrasonography: Intravesical prostatic protrusion andvelocity-flow video urodynamics. Urology 2005; 65:493-497.

7. Doo CK, Uh HS: Anatomic configuration of prostate obtained bynoninvasive ultrasonography can predict clinical voiding parametersfor determining BOO in men with LUTS. Urology 2009; 73:232-236.

8. Ku JH, Ko DW, Cho JY, Oh SJ: Correlation between prostatic ure-thral angle and bladder outlet obstruction index in patients with lowerurinary tract symptoms. Urology 2010; 75:1467-1471.

9. Lee LS, Sim HG, Lim KB, Wang D, Foo KT: Intravesical prostaticprotrusion predicts clinical progression of benign prostatic enlarge-ment in patients receiving medical treatment. Int J Urol 2010; 17:69-74.